Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Completed · Phase 3

Conditions studied: Renal Cell Carcinoma, Kidney Cancer

In brief

This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

Key facts

Study ID

NCT00606632

Run by

Heidelberg Pharma AG

People needed

226

Starts

2008-03-01

Expected to finish

2009-12-01

Last updated by the study team

2018-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is over 18 years of age.
• Presence of a renal mass.
• Scheduled for surgical resection of renal mass (partial or total nephrectomy, open or laparoscopic technique).
• Expected survival of at least 3 months.
• Eastern Cooperative Oncology Group (ECOG) performance status < 2.
• The following laboratory results should be within the following limits within the last 2 weeks prior to study day 1:
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
• Platelet count ≥ 100 x 109/L
• Serum bilirubin ≤ 2.0 mg/dL
• Aspartate aminotransaminase (AST) ≤ 2.5 x ULN
• Alanine aminotransferase (ALT) ≤ 2.5 x ULN
• Serum creatinine ≤ 2.0 mg/dL (calculated creatinine clearance >45 ml/min)
• Negative serum pregnancy test; to be performed on female patients of childbearing potential within 24 hours prior to receiving investigational product. All females of childbearing potential must indicate intent to avoid pregnancy and must use an accepted, effective method of contraception for the duration of the study.
• Recovered from toxicity of any prior therapy.
• Able and willing to give valid written informed consent.

You may not qualify if…

• Metastasis of primary tumor other than Renal Cell Carcinoma (RCC).
• Prior history of malignancy within the last 5 years.
• Prior exposure to murine proteins or chimeric antibodies.
• Intercurrent medical condition that may limit the amount of antibody to be administered.
• Intercurrent medical condition that renders the patient ineligible for surgery.
• New York Heart Association Class III/IV cardiac disease.
• History of autoimmune hepatitis.
• Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to 124I-cG250 infusion on day 1.
• Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
• Lack of availability for immunological and clinical follow-up assessments.
• Participation in any other clinical trial involving another investigational product within 4 weeks prior to enrolment.
• Women who are pregnant or breastfeeding.
• Allergy to iodine, hyperthyroidism, or Grave's Disease.
• Known allergic reaction to human serum albumin.
• Contraindication for contrast-enhanced CT or PET/CT.
• Contraindication to potassium iodide intake (see package insert).

Where it is running

• David Geffen School of Medicine, UCLA — Los Angeles, California, United States
• Stanford University Medical Center — Stanford, California, United States
• H. Lee Moffitt Cancer Center & Research Center — Tampa, Florida, United States
• Lahey Clinic — Burlington, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Nevada Cancer Institute — Las Vegas, Nevada, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• UNC School of Medicine-Chapel Hill — Chapel Hill, North Carolina, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Ohio State University — Columbus, Ohio, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• MD Anderson — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.